Biotech Stocks Surge After FDA Allows uniQure AMT-130 Refiling

FDA reversal lifts uniQure

uniQure shares surged on June 17 after the company said the U.S. Food and Drug Administration will allow it to refile for approval of AMT-130, its Huntington’s disease gene therapy, using a three-year analysis of existing Phase 1/2 trial data.

The shift is a sharp reversal from the agency’s earlier view that the available data were not enough to support a biologics license application. It also sent a read-through across biotechnology stocks, with market reports pointing to gains in broader biotech names and exchange-traded funds.

Investor’s Business Daily reported that uniQure rose 78.4% to 48.16 on the news, while Barron’s said the stock gained about 81% to 48.77. Both outlets framed the move as one of the most dramatic regulatory turns the company has faced this year.

From March setback to June reversal

The latest development came after months of regulatory uncertainty. Reporting in March indicated the FDA had said the Phase 1/2 package was not sufficient and had pointed to a randomized, double-blind follow-up study as the preferred route.

Barron’s said the agency had still been signaling as recently as March that another study would be needed. The June 17 change therefore represents not just a procedural adjustment, but a meaningful change in how the FDA appears willing to evaluate the existing dataset.

According to the research packet, the current position would let uniQure pursue a filing using the three-year data from its ongoing program. The exact wording of the FDA’s communication has not been independently confirmed in an official public release, but the available reporting points to the same core reversal.

What investors are reading into the move

AMT-130 is uniQure’s lead Huntington’s disease program and the main driver of the company’s pipeline value. That matters because Huntington’s is a severe neurodegenerative disease with no approved therapy that slows progression.

The result also carried broader market significance. Investor’s Business Daily reported that the FDA’s shift helped lift the medical-development biotech group and the XBI exchange-traded fund, with names such as Atara Biotherapeutics, Replimune, Moderna and Biohaven also moving higher.

Cantor Fitzgerald turned more constructive on uniQure after the news, according to Barron’s, upgrading the stock to Buy from Hold and raising its price target to $61 from $18.

What still has to happen

The new path does not eliminate risk. uniQure and the FDA still need to agree on the design of a confirmatory backup study, which could add time and execution complexity even if the agency now accepts a refiling.

That leaves investors watching for a formal submission and any FDA feedback on the application package. The company has not yet disclosed the full terms of the updated regulatory path in public detail.

The bigger question is whether the move marks a one-off break for uniQure or signals more flexibility from the FDA for other high-need biotech and gene-therapy programs. For now, the market is treating it as a major change in tone for one of the field’s closely watched drug candidates.